Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of obstructive jaundice on the pharmacodynamics of remazolam
ChiCTR2100043585Phase 4Not yet recruiting
- Sponsor
- Shidong Hospital
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of remimazolam mesylate in obstructive jaundice, chronic cholecystitis and hepatolithiasis (HL) (2 arms), sponsored by Shidong Hospital. Primary endpoint: Remazolam dose required. Planned start May 2021; status: not yet recruiting.
02
Drugs
remimazolam mesylate
03
Conditions
obstructive jaundicechronic cholecystitishepatolithiasis (HL)
Beyond the preview
Go deeper on ChiCTR2100043585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043585.